Previous preclinical studies on immune remodeling mechanisms in EGFR-mutant LUAD have mostly leveraged models that exogenously express EGFR mutants in EGFR wild-type murine tumor cell lines, primarily (such as) LLC and MC38 47-50. The gene discussed is EGFR; the disease is neoplasm.